Holen Sie sich die Stockscreener-App
68.95
1.56%
0.9729
Schlusskurs vom Vortag:
$67.98
Offen:
$68.81
24-Stunden-Volumen:
738.40K
Relative Volume:
0.27
Marktkapitalisierung:
$13.35B
Einnahmen:
$353.78M
Nettoeinkommen (Verlust:
$-805.69M
KGV:
-16.47
EPS:
-4.1869
Netto-Cashflow:
$-597.61M
1W Leistung:
+5.63%
1M Leistung:
-8.25%
6M Leistung:
+34.82%
1J Leistung:
+113.68%
1-Tages-Spanne:
$67.73
$70.00
1-Wochen-Bereich:
$64.50
$75.91
52-Wochen-Spanne:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
68.88 | 13.18B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.60 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.89 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf - Yahoo Finance
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - Yahoo Finance
BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9 - Citeline News & Insights
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - simplywall.st
BridgeBio reports Phase III progress for BBP-418 - The Pharmaletter
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga
Barclays Maintains Overweight on BridgeBio Pharma (BBIO) March 2026 - Meyka
Capital Research Global Investors Sells 2,055,172 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Leerink Maintains Outperform on BBIO, BridgeBio Pharma, Inc. March 12, 2026 - Meyka
BridgeBio (BBIO) Reports Promising Phase 3 Data for BBP-418 in M - GuruFocus
BridgeBio Pharma Presents Promising Phase 3 FORTIFY Interim Analysis Results for BBP-418 in LGMD2I/R9 at MDA Conference - Quiver Quantitative
Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026 - TradingView
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 - Yahoo Finance
BridgeBio (BBIO) Reports Wider Q4 Loss of $1/Share vs $0.63 Estimate; Stock Surges 13% - AlphaStreet
HC Wainwright Raises Earnings Estimates for BridgeBio Pharma - MarketBeat
BridgeBio (BBIO) Sees Price Target Boost and Earns Overweight Ra - GuruFocus
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
U.S. Indexes Finished Mixed Tuesday As BridgeBio Pharma Led, Centene Lagged - Barron's
Barclays reiterates Overweight on BridgeBio Pharma stock By Investing.com - Investing.com Canada
BridgeBio’s Price Target Boost Sparks Investor Excitement - StocksToTrade
Why Is BridgeBio Pharma Stock Soaring Tuesday?BridgeBio Pharma (NASDAQ:BBIO) - Benzinga
JP Morgan Raises Price Target for BridgeBio Pharma (BBIO) to $94 - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 9.3%Should You Buy? - MarketBeat
BridgeBio Pharma shares jump as investors focus on fresh BBP-418 data at MDA meeting and near-term regulatory milestones - Quiver Quantitative
BridgeBio Pharma’s Surge: A Closer Look at Market Dynamics - StocksToTrade
BridgeBio Pharma’s Growth Momentum Backed by Analyst Confidence - timothysykes.com
BridgeBio Pharma Jumps as Wall Street Piles In - TipRanks
William Blair initiates BridgeBio stock with outperform rating - Investing.com India
William Blair initiates BridgeBio stock with outperform rating By Investing.com - Investing.com South Africa
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at William Blair - MarketBeat
FY2027 Earnings Estimate for BBIO Issued By HC Wainwright - MarketBeat
Victory Capital Management Inc. Purchases 141,800 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Bitget
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline - Yahoo Finance
Andrea Ellis Sells 64,921 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com South Africa
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares By Investing.com - Investing.com UK
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating - Bitget
(BBIO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GW&K Investment Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms - MarketBeat
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - Bitget
BridgeBio Pharma to Present Phase 3 FORTIFY Trial Data on LGMD2I/R9 Therapy at 2026 MDA Conference - geneonline.com
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com Australia
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com Nigeria
TD Asset Management Inc Purchases Shares of 88,950 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Valantine Hannah | Director |
Mar 10 '26 |
Sale |
72.00 |
8,671 |
624,312 |
7,465 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):